It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inhibition of DNA binding proteins 1 and 3 (ID1 and ID3) are important downstream targets of BMP signalling that are necessary for embryonic development. However, their specific roles in regulating the pluripotency of human embryonic stem cells (hESCs) remain unclear. Here, we examined the roles of ID1 and ID3 in primed and naive-like hESCs and showed that ID1 and ID3 knockout lines (IDs KO) exhibited decreased survival in both primed and naive-like state. IDs KO lines in the primed state also tended to undergo pluripotent dissolution and ectodermal differentiation. IDs KO impeded the primed-to-naive transition (PNT) of hESCs, and overexpression of ID1 in primed hESCs promoted PNT. Furthermore, single-cell RNA sequencing demonstrated that ID1 and ID3 regulated the survival and pluripotency of hESCs through the AKT signalling pathway. Finally, we showed that TCF3 mediated transcriptional inhibition of MCL1 promotes AKT phosphorylation, which was confirmed by TCF3 knockdown in KO lines. Our study suggests that IDs/TCF3 acts through AKT signalling to promote survival and maintain pluripotency of both primed and naive-like hESCs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Zhejiang University School of Medicine, Hangzhou, Department of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
2 Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
3 Zhejiang University School of Medicine, Hangzhou, Department of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
4 The First Affiliated Hospital of Wenzhou Medical University, Department of Pulmonary and Critical Care Medicine, Wenzhou, China (GRID:grid.414906.e) (ISNI:0000 0004 1808 0918)
5 Zhejiang University School of Medicine, Division of Human Reproduction and Developmental Genetics, Women’s Hospital and Institute of Genetics, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
6 Zhejiang University School of Medicine, Department of human anatomy and histoembryology, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
7 University of Cambridge, Department of Medicine, National Institute of Health Research Cambridge Biomedical Research Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
8 Department of Gastroenterology of The Children’s Hospital, Institute of Genetics, Zhejiang University School of Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)